Valeant revoking CEO Joseph Papa’s $29.8M stock award — 4 insights

Valeant Pharmaceuticals is revoking CEO Joseph Papa’s $29.8 million stock award, as it revamps its management compensation program, the Financial Post reports.

Advertisement

Here’s what you should know.

1. Valeant also revoked CFO Paul Herendeen’s award.

2. Both executives received large upfront equity awards when they were hired in 2016. They’ll instead get smaller annual grants.

3. The grants will vest if the company increases its stock value to certain figures.

4. Mr. Papa will receive a $10 million long-term incentive package this year. He wasn’t awarded any equity in 2017.

More articles on supply chain:
Nobilis looking for more large in-network acquisitions in 2018: 5 key quotes from CEO Harry Fleming
Congress questions Joint Commission accreditation process — 7 insights
Common deficiencies cited by AAAASF and how to fix them: Administration of drugs

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Rethinking Safety and Security in the Healthcare Environment

Thursday, July 23
1:00 PM - 2:00 PM CDT

Presenters: Jon Share, AxonDan Snyder, Advocate HealthKeith Hunter, Wellstar

Advertisement

Next Up in Supply chain

Advertisement

Comments are closed.